Peter Thomson Net Worth & Insider Trades
Peter Thomson - VP Finance & Accounting, Fulcrum Therapeutics, Inc
What is Peter Thomson's Net Worth?
The current estimated net worth of Fulcrum Therapeutics, Inc's VP Finance & Accounting, Peter Thomson, is estimated to be about $561.41K . Peter Thomson owns about 2,300 units of Fulcrum Therapeutics, Inc common stock. In the last 3 years at Fulcrum Therapeutics, Inc, Peter Thomson has sold an estimated value of $456.33K worth.
What is Peter Thomson's Past Insider Trading?
Peter Thomson's largest purchase order was 5,000 units , worth over $39.2K on February 24, 2021. Peter Thomson's largest sale order was 7,500 units , worth over $120K on May 12, 2020. In total, Peter Thomson has made about 9 transactions over 3 years of their time at Fulcrum Therapeutics, Inc. Peter Thomson usually trades in January, with the busiest year in 2021. The most recent transaction was a purchase order of 2,300 units , worth over $20.7K on June 29, 2021.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Peter Thomson
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
InsideArbitrage
What is Peter Thomson's' Mailing Address?
- Mailing address is C/o Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge MA 02139 MA
What are Fulcrum Therapeutics, Inc's Past Insider Trades?
Fulcrum Therapeutics, Inc's most recent insider trade came on May 11, 2023 by Greg Tourangeau who sold 210 units worth $695.1 . In the last 4 years, insiders at Fulcrum Therapeutics, Inc have sold an estimated value of $7.48M and bought an estimated value of $52.6M worth of shares. Insider trading is most common in June, with the busiest year in 2020. The most active traders at the company are Robert J Gould, Interim President & CEO, Diego Cadavid, SVP Clinical Development, and Owen B Wallace, Chief Scientific Officer .
Fulcrum Therapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |